NASDAQ$LQDA
Liquidia Corporation · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Liquidia reported financial results for the third quarter ended September 30, 2022.
Liquidia reported revenue of $3.2 million and a net loss of $9.1 million for the third quarter of 2022. The company's cash totaled $98.3 million as of September 30, 2022. They are awaiting decisions on YUTREPIA™ (treprostinil) inhalation powder.
- The PTAB found in favor of Liquidia in the ‘793 IPR stating that all the claims of the ‘793 Patent have been shown to be unpatentable.
- The Court ruled in Liquidia’s favor with respect to the ‘066 Patent, finding that five of the six asserted claims of the '066 Patent are invalid and that the remaining asserted claim is not infringed by Liquidia.
- Unless UTC is successful in overturning at least one of the decisions that have been rendered, the Company will be able to launch YUTREPIA following completion of the appeals process.
- Cash totaled $98.3 million as of September 30, 2022, compared to $57.5 million as of December 31, 2021.
Headline financials
Revenue & EPS history
Liquidia · Revenue · Quarterly
$3.17M
Revenue by segment
Liquidia · $3.2M total across 1 segment · Q3 2022
- Promotion Agreement$3.2M+0.0%100.0%
Forward guidance
Timeline for a prospective launch will be primarily governed by the resolution of UTC’s expected appeal of the ‘793 IPR decision.
Tailwinds
- The PTAB found in favor of Liquidia in the ‘793 IPR stating that all the claims of the ‘793 Patent have been shown to be unpatentable.
- The Court ruled in Liquidia’s favor with respect to the ‘066 Patent, finding that five of the six asserted claims of the '066 Patent are invalid and that the remaining asserted claim is not infringed by Liquidia.
- Data from the completed INSPIRE study were published in the journal Pulmonary Circulation, highlighting observations from patients treated for an average of one year.
- YUTREPIA was safely dosed from 26.5 mcg to 212 mcg, which are comparable to 3 to 24 breaths of nebulized Tyvaso® per session.
- Patients maintained or improved in exploratory measures of clinical efficacy, whether prostacyclin naïve or transitioning from Tyvaso.
Headwinds
- The decisions of the Court and the PTAB are all subject to ongoing rehearing requests and appeals.
- If the PTAB denies the rehearing request, we anticipate that the timeline for the completion of the appeal to the Court of Appeals for the Federal Circuit could be approximately 12-14 months from the date on which the rehearing request is denied.
- The increase of $1.8 million or 38% was primarily due to a $2.2 million increase in commercial, marketing, and personnel expenses in preparation for the potential commercialization of YUTREPIA offset by a $0.9 million decrease in legal fees related to our ongoing YUTREPIA-related litigation.
- Net loss for the three months ended September 30, 2022, was $9.1 million, or $0.14 per basic and diluted share, compared to a net loss of $7.3 million, or $0.14 per basic and diluted share, for the three months ended September 30, 2021.
- Other Expenses net total was $0.3 million for the three months ended September 30, 2022, compared with $0.2 million for the three months ended September 30, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
+3.4%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+1.7%
Avg return
30 days after
60%
18 / 30 earnings
Positive
+31.8%
Q2 2022
Best reaction
-13.3%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +25.4% | +34.5% | — | |
| Q4 2025 | +0.4% | +12.9% | +9.6% | |
| Q3 2025 | +8.8% | +7.1% | +38.5% | |
| Q1 2025 | -1.0% | +3.0% | +16.8% | |
| Q4 2024 | +1.2% | +6.2% | -6.9% | |
| Q3 2024 | -5.6% | -7.6% | +2.7% | |
| Q2 2024 | +2.9% | +10.4% | -17.7% | |
| Q1 2024 | -0.8% | +5.4% | +10.4% | |
| Q4 2023 | +9.6% | +11.3% | -0.2% | |
| Q3 2023 | -1.0% | -4.4% | +9.8% | |
| Q2 2023 | -6.3% | -8.9% | -7.5% | |
| Q1 2023 | +5.0% | +7.8% | +26.1% | |
| Q4 2022 | +13.5% | +13.2% | +6.3% | |
| Q3 2022 | +0.8% | -0.4% | +14.6% | |
| Q2 2022 | +31.8% | +34.5% | +9.9% | |
| Q1 2022 | +7.7% | +21.9% | -17.0% | |
| Q4 2021 | +11.2% | +9.7% | -17.8% | |
| Q3 2021 | +9.9% | +9.7% | +3.1% | |
| Q2 2021 | -0.8% | +11.8% | +16.4% | |
| Q1 2021 | -0.7% | +0.0% | -0.7% | |
| Q4 2020 | -7.4% | -6.6% | +2.2% | |
| Q3 2020 | +0.7% | -12.7% | -36.9% | |
| Q2 2020 | -13.3% | -8.5% | -23.3% | |
| Q1 2020 | +8.0% | +8.7% | +13.4% | |
| Q4 2019 | -1.5% | +1.7% | +54.5% | |
| Q3 2019 | +5.2% | +0.6% | +6.4% | |
| Q2 2019 | +6.4% | -0.7% | -40.6% | |
| Q1 2019 | -3.0% | -0.4% | +2.6% | |
| Q4 2018 | +3.0% | +3.1% | -43.8% | |
| Q3 2018 | -9.2% | -1.3% | +19.4% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro